Early versus delayed treatment with laquinimod demonstrated significant reduction in risk of disability progression – Results of three-year ALLEGRO study in relapsing-remitting multiple sclerosis
Teva Pharmaceutical Industries Ltd., 21 Mar 2013
Accessed on 25 Mar 2013 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1798762.